Join
Live feed
·
INSIDERFilingvia Quantisnow
Dyne Therapeutics Inc. logo

Chief Commercial Officer Friedl-Naderer Johanna was granted 60,000 shares, increasing direct ownership by 63% to 154,729 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
DYN· Dyne Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DYN (Dyne Therapeutics Inc.) and more on Quantisnow.